Natural Alternatives International's Fiscal Year Overview
Natural Alternatives International, Inc. ('NAI') (Nasdaq: NAII) has reported its financial performance for the fourth quarter and the entire fiscal year. The company marked a net loss of $7.2 million or ($1.20) per diluted share, alongside net sales of $33.9 million during the fourth quarter of the fiscal year. In comparison, the company faced a net loss of $1.9 million or ($0.32) per diluted share in the same quarter of the previous fiscal year.
Sales Performance Analysis
The quarterly net sales showcased an impressive increase of 15%, rising by $4.4 million from $29.5 million in the corresponding period last year to $33.9 million this year. This surge is primarily fueled by a 15% hike in private-label contract manufacturing sales, now totaling $31.8 million. The increase stems from heightened orders from existing clientele and fresh orders from new customers, though it was slightly tempered by a reduction in orders from one major client.
Growth in CarnoSyn® Beta-Alanine Sales
In the same period, revenue from CarnoSyn® beta-alanine, which encompasses royalty, licensing, and raw material sales, rose by 14% to $2.1 million compared to $1.8 million from the last year's fourth quarter. The uptick is attributed to higher raw material sales to existing customers along with an increase in royalty income from this innovative product.
Fiscal Year 2025: Overall Performance
The total net loss recorded for the entirety of fiscal 2025 stands at $13.6 million or ($2.28) per diluted share, a substantial rise from the net loss of $7.2 million or ($1.23) per diluted share documented for fiscal 2024. Just like in the quarterly performance, the fiscal year results were influenced by non-recurring charges associated with litigation settlements and a valuation allowance against deferred tax assets. Excluding said charges, the adjusted net loss for 2025 would reflect at around $7.4 million.
Improved Sales Figures for Fiscal Year
Throughout the fiscal year, net sales surged to $129.9 million, a 14% rise or $16.1 million more than the $113.8 million recorded in the prior year. Private-label contract manufacturing sales accelerated by 16% to $121.8 million compared to $105.4 million previously. However, revenue from CarnoSyn® products dipped slightly by 4% to $8.1 million from $8.4 million.
Future Outlook
The company acknowledged that despite achieving sales growth in the last quarter and across the entire fiscal year, operational losses were driven by inefficient utilization of factory capacities, the financial impact of tax asset valuations, and litigation matters. Moving into fiscal 2026, NAI anticipates a significant increase in sales, aiming for profit in the second half of the year after an expected net loss in the first.
Balance Sheet Highlights
As of the year-end, NAI reported a cash balance of $12.3 million and working capital of $30.5 million compared to $12.0 million and $38.1 million from the previous year, respectively. They also held a borrowing capacity of $9.9 million against a credit facility, with ongoing borrowings totalling $1.9 million.
Insights from Leadership
Mark A. Le Doux, Chairman and CEO of NAI, expressed discontent with the final quarter's results, attributing the negative outcome to the financial implications of the litigation settlement and deferred tax asset adjustments. However, he highlighted a positive trend in revenue and noted a preliminary optimistic outlook for the forthcoming year, saying, "Our focus remains on expanding our client base, diversifying channels, and improving processes to boost our revenue streams and profitability. We sincerely hope to achieve profitability for fiscal 2026. We are committed to maximizing the benefits that our unique TriBsyn™ formulation offers to improve health outcomes, especially for aging demographics by addressing critical health issues like sarcopenia and cardiovascular function.”
Frequently Asked Questions
What is Natural Alternatives International, Inc. known for?
Natural Alternatives International, Inc. is a prominent formulator, manufacturer, and marketer of customized nutritional supplements.
How did NAI perform in Q4 of fiscal year 2025?
The company reported a net loss of $7.2 million with net sales reaching $33.9 million, a 15% increase from the prior year.
What are CarnoSyn® products?
CarnoSyn® is a highly bioavailable beta-alanine supplement that NAI manufactures, used primarily in sports nutrition.
What factors contributed to NAI's net loss?
The net loss was influenced by non-recurring charges, underutilization of the factory, and the financial implications of a litigation settlement.
What are the expectations for fiscal year 2026?
NAI anticipates a net loss in the first half, followed by profitability in the second half of fiscal year 2026.
